The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Lilly’s Lupus Treatment Succeeds in Mid-Stage Trial

Lilly’s Lupus Treatment Succeeds in Mid-Stage Trial

June 14, 2018 • By Tamara Mathias

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Eli Lilly & Co said its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year.

You Might Also Like
  • AbbVie’s Rheumatoid Arthritis Drug Succeeds in Late-Stage Trial
  • Psoriasis Drug Succeeds in Mid-Stage Study
  • AbbVie’s RA Drug Succeeds in Late Stage Study

The data come two weeks after U.S. health regulators approved the drug, baricitinib, under the trade name Olumiant, with a far more restrictive label than expected to treat rheumatoid arthritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are few available treatments for lupus.

After 24 weeks of therapy, 67 percent of patients on a 4 mg dose of baricitinib showed a resolution of arthritis or rash, common symptoms of lupus, compared with 53 percent on a placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

However, baricitinib’s 2 mg dose did not show a statistically significant improvement.

Lilly’s once-daily pill belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes, known as Janus kinases, and Lilly says it is ahead of the curve in testing the drug in lupus patients.

“This is the first of this class of therapies to have shown this sort of benefit and we want to make the most of that,” Lilly’s global development leader, Jim McGill, told Reuters, adding that he expects other JAK inhibitor companies to jump in soon.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The data was presented at the annual European Congress of Rheumatology in Amsterdam.

The upcoming 52-week lupus trial will evaluate both doses of the drug, which is also being tested for eczema.

Lilly has partnered with Incyte Corp on the development of baricitinib.

Filed Under: Drug Updates Tagged With: Annual European Congress of Rheumatology, baricitinib, Eli Lilly & Co, JAK inhibitors, Lupus, lupus treatment, mid-stage trial, Olumiant

You Might Also Like:
  • AbbVie’s Rheumatoid Arthritis Drug Succeeds in Late-Stage Trial
  • Psoriasis Drug Succeeds in Mid-Stage Study
  • AbbVie’s RA Drug Succeeds in Late Stage Study
  • Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.